NVST is in a clear recovery uptrend, with the stock price up 25.05% over the past year, significantly outperforming the S&P 500's 20.63% gain. The current price of $25.91 sits at 67.7% of its 52-week range ($18.77 to $30.42), indicating the stock has rebounded strongly from its lows but still has room to run before challenging resistance. This positioning suggests bullish momentum is intact, though it is not yet overextended near the highs. Short-term momentum is mixed: the 1-month price change is +7.69%, accelerating from the 3-month change of -1.82%, which shows a recent sharp reversal. The 1-month relative strength versus the S&P 500 is +3.62%, confirming near-term outperformance. However, the 3-month relative strength is -12.93%, indicating that the stock lagged the market in the prior quarter, and the recent uptick may signal a trend reversal. The stock's beta of 0.86 implies it is less volatile than the market, which is consistent with its steady recovery pattern. Key support is at the 52-week low of $18.77, while resistance is at the 52-week high of $30.42. A breakout above $30.42 would signal a new uptrend leg, while a breakdown below $18.77 would negate the recovery. The current price is well above support, suggesting a healthy base.

Revenue growth is accelerating: the most recent quarter (Q4 2025) reported revenue of $750.6 million, up 14.96% year-over-year, compared to 6.9% growth in Q4 2024. The trailing twelve-month revenue is approximately $2.72 billion, with the Specialty Products & Technologies segment contributing $1.21 billion and Equipment & Consumables adding $679 million, indicating that the higher-margin specialty segment is the primary growth driver. This acceleration suggests that the company is gaining market share and benefiting from new product launches. Profitability has improved markedly: net income in Q4 2025 was $32.9 million, a sharp turnaround from the $1.2 million in Q4 2024 and a loss of $30.3 million in Q3 2025. Gross margin remained stable at 55.0%, while operating margin expanded to 10.1% from 7.1% a year ago, reflecting better cost control and operating leverage. The net margin of 4.4% is still below industry averages for dental equipment companies (typically 10-15%), but the trend is positive. The balance sheet is solid: debt-to-equity is 0.51, and the current ratio is 2.38, indicating ample liquidity. Free cash flow for the quarter was $91.7 million, and the company ended with $1.21 billion in cash, providing flexibility for investments or share buybacks. ROE is low at 1.5%, but this is expected to improve as earnings recover from the prior year's impairment charges.